Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival

2 Pogledi
administrator
administrator
07/10/23

The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).

  • Kategorija

Prikaži više

0 Komentari Poredaj po

Nema komentara

Komentari na Facebooku

Sljedeći